TECH

Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Bio-Techne (NASDAQ:TECH) and the best and worst performers in the research tools & consumables industry. The life sciences subsector specializing in research tools and consumables enables scientific discoveries across academia, biotechnology, and pharmaceuticals. These firms supply a wide range of essential laboratory products, ensuring a recurring revenue stream through repeat purchases and replenishment. Their business models benefit from strong customer loyalty, a diversified product portfolio, and exposure to both the research and clinical markets. However, challenges include high R&D investment to maintain technological leadership, pricing pressures from budget-conscious institutions, and vulnerability to fluctuations in research funding cycles. Looking ahead, this subsector stands to benefit from tailwinds such as growing demand for tools supporting emerging fields like synthetic biology and personalized medicine. There is also a rise in automation and AI-driven solutions in laboratories that could create new opportunities to sell tools and consumables. Nevertheless, headwinds exist. These companies tend to be at the mercy of supply chain disruptions and sensitivity to macroeconomic conditions that impact funding for research initiatives. The 10 research tools & consumables stocks we track reported a mixed Q1. As a group, revenues beat analysts’ consensus estimates by 1.3% while next quarter’s revenue guidance was 2% above. Luckily, research tools & consumables stocks have performed well with share prices up 21.8% on average since the latest earnings results. With a catalog of hundreds of thousands of specialized biological products used in laboratories worldwide, Bio-Techne (NASDAQ:TECH) develops and manufactures specialized reagents, instruments, and services that help researchers study biological processes and enable diagnostic testing and cell therapy development. Bio-Techne reported revenues of $311.4 million, down 1.5% year on year. This print fell short of analysts’ expectations by 1.6%. Overall, it was a softer quarter for the company with a miss of analysts’ organic revenue estimates and EPS in line with analysts’ estimates. "The Bio‑Techne team delivered solid execution amid a mixed end‑m...

US equity markets were pointing higher before the opening bell Thursday as traders parse Micron Tech

(Updates with index/price moves, macroeconomic data, and company/political news from the first parag

The Dow Jones Industrial Average and S&P 500 were up in late-morning trading Thursday, while the Nas

A month has gone by since the last earnings report for Techne (TECH). Shares have added about 4.5% in that time frame, outperforming the S&P 500. Will the recent positive trend continue leading up to its next earnings release, or is Techne due for a pullback? Well, first let's take a quick look at its latest earnings report in order to get a better handle on the recent drivers for Bio-Techne Corp before we dive into how investors and analysts have reacted as of late. Bio-Technereported third-quarter fiscal 2026 adjusted earnings per share of 53 cents, which missed the Zacks Consensus Estimate by 2.8%. The bottom line was down 5.4% on a year-over-year basis. The quarter's adjustments eliminated the impact of certain one-time items, including amortization of Wilson Wolf intangible assets, and restructuring and restructuring-related costs, among others. GAAP earnings per share was 32 cents compared with 14 cents in the prior-year quarter. Bio-Techne registered net sales of $311.4 million, reflecting a decline of 1.5% year over year on a reported basis. The figure was down 2% on an organic basis. The top line missed the Zacks Consensus Estimate by 2.4%. Following the announcement, shares of Bio-Techne declined 1.2% in pre-market trading yesterday, reflecting investor reaction to the company’s quarterly sales and earnings decline. The company reports under two business segments — Protein Sciences, and Diagnostics and Spatial Biology (formerly Diagnostics and Genomics). Within Protein Sciences, Bio-Techne recorded revenues of $226.2 million, down 1% year over year (down 4% organically). In fiscal 2024, a business within this segment met the criteria as held-for-sale, excluded from its operating results. Within Diagnostics and Spatial Biology, sales decreased 4% year over year to $85.6 million (up 3% organically) in the fiscal third quarter. Within this, the Exosome Diagnostics business met the held-for-sale criteria, excluded from its operating results. Bio-Techne’s gross profit fell 2.9% to $208.3 million. The gross margin contracted 97 basis points (bps) to 66.9% on a 1.5% rise in the cost of sales. Selling, general and administrative expenses declined 27.7% to $109.3 million. Research and development expenses totaled $23.4 million, down 4.6% year over year. The company generated an operating profit of $75.5 million in the fiscal third quarter compared with the...

Bio-Techne’s first quarter was marked by a negative market reaction, with revenue coming in below Wall Street expectations. Management attributed the shortfall primarily to continued softness in emerging biotech demand and the impact of order timing from two cell therapy customers with FDA Fast Track Designation. CEO Kim Kelderman acknowledged that, despite stable performance from large pharmaceutical customers and improving trends in U.S. academia, the emerging biotech segment “was indeed our surprise,” as early-stage funding remained weak and order activity lagged expectations. Is now the time to buy TECH? Find out in our full research report (it’s free). Revenue: $311.4 million vs analyst estimates of $316.4 million (1.5% year-on-year decline, 1.6% miss) Adjusted EPS: $0.53 vs analyst estimates of $0.53 (in line) Adjusted EBITDA: $116.7 million vs analyst estimates of $115.4 million (37.5% margin, 1.1% beat) Operating Margin: 24.2%, up from 12.2% in the same quarter last year Organic Revenue fell 2% year on year (miss) Market Capitalization: $7.42 billion While we enjoy listening to the management's commentary, our favorite part of earnings calls are the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention. Matthew Larew (William Blair) asked about intra-quarter biotech trends; CEO Kim Kelderman explained that, despite stronger funding, early-stage biotech funding was still down and customer order activity remained muted. Puneet Souda (Leerink Partners) questioned the potential for mid-single-digit growth next year; CFO James Hippel said he would be disappointed if that was not achieved, citing normalization trends and core business resilience. Patrick Donnelly (Citi) inquired about China’s outlook; Kelderman said the team expects continued momentum in China, citing direct market presence and strong customer ties as drivers. Justin Bowers (Deutsche Bank) sought clarity on early signs of a biotech recovery; Hippel pointed to rising interest and funnel growth within proteomic analysis and spatial biology as leading indicators, but cautioned that order conversion is not yet evident. Kyle Boucher (TD Cowen) asked about the sustainability of high growth in GMP reagent and spatial biology; Kelderman responded that deeper cu...

Bio-Techne Corporation's (NASDAQ:TECH) earnings announcement last week didn't impress shareholders. However, our analysis suggests that the soft headline numbers are getting counterbalanced by some positive underlying factors. AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early. To properly understand Bio-Techne's profit results, we need to consider the US$157m expense attributed to unusual items. It's never great to see unusual items costing the company profits, but on the upside, things might improve sooner rather than later. We looked at thousands of listed companies and found that unusual items are very often one-off in nature. And, after all, that's exactly what the accounting terminology implies. Bio-Techne took a rather significant hit from unusual items in the year to March 2026. All else being equal, this would likely have the effect of making the statutory profit look worse than its underlying earnings power. That might leave you wondering what analysts are forecasting in terms of future profitability. Luckily, you can click here to see an interactive graph depicting future profitability, based on their estimates. As we mentioned previously, the Bio-Techne's profit was hampered by unusual items in the last year. Based on this observation, we consider it possible that Bio-Techne's statutory profit actually understates its earnings potential! On the other hand, its EPS actually shrunk in the last twelve months. Of course, we've only just scratched the surface when it comes to analysing its earnings; one could also consider margins, forecast growth, and return on investment, among other factors. In light of this, if you'd like to do more analysis on the company, it's vital to be informed of the risks involved. While conducting our analysis, we found that Bio-Techne has 1 warning sign and it would be unwise to ignore it. Today we've zoomed in on a single data point to better understand the nature of Bio-Techne's profit. But there is always more to discover if you are capable of focussing your mind on minutiae. Some people consider a high return on equity to be a good sign of a quality business. So you may wish to see this free collection of companies boasting high return on equity, or this list of...

Image source: The Motley Fool. Wednesday, August 6, 2025 at 9 a.m. ET President and Chief Executive Officer — Kim Kelderman Chief Financial Officer — James T. Hippel Kim Kelderman: Thank you, Dave, and good morning, everyone. Welcome to Bio-Techne's Fiscal Fourth Quarter 2025 Earnings Call. I'm pleased to report that we delivered a solid quarter that was in line with our expectations. The team's continued execution drove 3% organic revenue growth in a dynamic operating environment. Our performance was once again fueled by strength in the biopharma end markets, particularly among large pharma customers, which fueled robust demand for our automated proteomic analytical instrumentation and cell therapy solutions. Our fourth quarter capped off a fiscal year in which we delivered 5% organic revenue growth. We reinforced our leadership across key markets through a series of innovative product launches, and we positioned the company for sustained future growth. As a reminder, approximately 80% of Bio-Techne's revenue is derived from consumables, including those used for our proprietary instrumentation, and this provides a strong foundation for durable growth. This resilient revenue mix, combined with the critical value our customers place in our portfolio of tools for research, manufacturing and precision diagnostics was reflected in our differentiated financial performance despite uncertainties many of our customers faced throughout 2025. This performance was once again achieved with a strong emphasis on profitability. The operational efficiencies we continue to implement contributed to an adjusted operating margin of 32% for the quarter. Our team remains focused on striking the right balance between investing for future growth and driving productivity across the organization. This disciplined approach enables us to maintain our industry-leading profitability while positioning Bio-Techne for long-term success. Before we delve into the quarterly performance, I want to highlight a strategic portfolio action that reflects our long-term financial and operational priorities. Last night, we announced the divestiture of our Exosome Diagnostics business, including the ExoDx prostate test and our CLIA-certified clinical laboratory to MDxHealth, a recognized leader in urology and specifically prostate cancer diagnostics. Following a thorough strategic assessment, we conclud...

Image source: The Motley Fool. Oct. 30, 2024 at 9 a.m. ET President and Chief Executive Officer — Kim Kelderman Chief Financial Officer — Jim Hippel Need a quote from a Motley Fool analyst? Email [email protected] Kim Kelderman, President and Chief Executive Officer; and Jim Hippel, Chief Financial Officer of Bio-Techne. Before we begin, let me briefly cover our safe harbor statement. Some of the comments made during this conference call may be considered forward-looking statements, including beliefs and expectations about the company's future results. The company's 10-K for fiscal year 2024 identifies certain factors that could cause the company's actual results to differ materially from those projected in the forward-looking statements made during this call. The company does not undertake to update any forward-looking statements because of any new information or future events or developments. The 10-K, as well as the company's other SEC filings, are available on the company's website within its Investor Relations section. During the call, non-GAAP financial measures may be used to provide information pertinent to ongoing business performance. Tables reconciling these measures to most comparable GAAP measures are available in the company's press release issued earlier this morning on the Investor Relations section of our Bio-Techne Corporation website at www.bio-techne.com. Separately, in the coming weeks, we will be participating in the UBS, Stifel, Stephens and Jefferies conferences. We look forward to connecting with many of you at these upcoming events. I will now turn the call over to Kim. Kim Kelderman: Thanks, Dave, and good morning, everyone. Thank you for joining us for our first quarter conference call. I'm pleased to report that the start to our fiscal year 2025 was largely consistent with our initial expectation. Continued stabilization of our biopharma end-markets combined with excellent execution by the Bio-Techne team led to 4% year-over-year organic revenue growth. Our growth pillars, including our molecular Diagnostics or Spatial Biology platforms, as well as our proteomic analysis franchise continued to outperform in constrained end-markets. It's also encouraging to see early indications of improvements in our biotech end-markets, which is validated by the strength we experienced in our cell and gene therapy business during this last quarter. I'...

Image source: The Motley Fool. Wednesday, May 6, 2026 at 9:00 a.m. ET President and Chief Executive Officer — Kim Kelderman Chief Financial Officer — James Hippel Kim Kelderman: Thank you, Dave, and good morning, everyone. Welcome to Bio-Techne's Third Quarter Earnings Call for Fiscal 2026. The Bio-Techne team continued to execute with discipline in a dynamic and uneven end market environment. Our quarterly performance was supported by sustained strength from our large pharmaceutical customers and stable to improving trends in our U.S. academic end market. These positives were partially offset by continued softness in emerging biotech spending, resulting in a 2% organic revenue decline for the quarter. Importantly, we are seeing encouraging indicators that point to an ongoing improvement in the U.S. academia and an eventual recovery in emerging biotech, which positions us well for a stronger fiscal 2027. As discussed in our prior earnings call, order timing related to 2 cell therapy customers that received FDA Fast Track Designation along with the timing of a large OEM commercial supply order created a 400 basis point headwind in the quarter. Excluding these factors, underlying organic revenue growth was 2%. There were several notable highlights during our third quarter, including the following: our Spatial Biology portfolio delivered mid-teens growth and exited the quarter with another record backlog for our COMET platform. Our GMP protein portfolio grew nearly 50% year-over-year when excluding the 2 fast track cell therapy customers. Within our Proteomic Analysis franchise, favorable instrument placements and utilization trends drove mid-single-digit growth. Our China end market achieved positive organic growth for the fourth consecutive quarter. And our largest end market, large pharma, delivered its sixth consecutive quarter of double-digit growth. We also remained highly focused on profitability. Adjusted operating margin in the third quarter was 34.2%, representing a 310 basis point sequential improvement over fiscal Q2. Jim will provide additional detail on our financial performance later in the call. Now I turn to our end markets, beginning with biopharma, excluding cell therapy. Here, we continue to see a divergence between the performance of large pharma and the performance of emerging biotech. Revenue from our large pharma customers grew low doubl...

Performance was characterized by a sharp divergence between large pharma, which delivered its sixth consecutive quarter of double-digit growth, and emerging biotech, which declined high single digits. Organic revenue declined 2% overall, but underlying growth was 2% when excluding a 400 basis point headwind from order timing and clinical acceleration of two fast-track cell therapy customers. The U.S. academic market returned to growth as NIH budget clarity and increased grant activity reduced funding uncertainty, signaling a shift from stabilization to gradual improvement. China achieved its fourth consecutive quarter of positive organic growth, driven by demand for antibody-drug conjugates and autoimmune research reagents. Management implemented a strategic brand alignment, consolidating ten brands into three (R&D Systems, Spatial Biology, and Diagnostics) to simplify customer engagement across the clinical continuum. AI is being leveraged internally for novel protein design and externally as a demand driver for high-quality biological data sets required to validate AI-enabled drug discovery models. Profitability remained a priority, with adjusted operating margins improving 310 basis points sequentially to 34.2% through disciplined expense management and structural streamlining. Management expects approximately flat organic growth in Q4, assuming end-market conditions remain consistent with Q3 levels. A meaningful uptick in emerging biotech spending is anticipated in the first half of fiscal 2027, following the typical two-to-three quarter lag from the recent rebound in biotech funding. The specific headwind from fast-track cell therapy customers is expected to moderate to 150 basis points in Q4 and roll off completely by fiscal 2027. Fiscal 2027 is positioned for acceleration as academic conditions normalize, company-specific headwinds lap, and easier year-over-year comparisons take effect. The company remains on track to acquire the remainder of Wilson Wolf by the end of calendar 2027, or potentially earlier based on milestone achievements. Two major cell therapy customers receiving FDA Fast Track Designation reduced near-term GMP reagent demand as they already secured materials for accelerated clinical timelines. Unfavorable product mix and volume deleverage impacted adjusted gross margins, which declined to 70.4% from 71.6% in the prior year. The dives...

Interested in Bio-Techne Corp? Here are five stocks we like better. Bio-Techne reported Q3 revenue of $311.4 million, a 2% decline on both reported and organic bases; management said ~400 basis points of the weakness came from timing related to two Fast‑Track cell‑therapy customers and a shifted OEM order, and that underlying organic growth was +2% after adjusting for those items. End markets were uneven: large pharma grew low double‑digits while emerging biotech fell high single‑digits despite a funding rebound, academia returned to low single‑digit growth; segment strength was led by Spatial Biology (mid‑teens growth and a COMET backlog) while Protein Sciences was pressured though GMP protein sales were much stronger when adjusted for timing. Profitability and cash generation improved sequentially (adjusted operating margin 34.2%, operating cash flow $86.7 million), net debt declined and leverage is below 1x EBITDA; management expects Q4 organic growth to be “approximately flat” and is targeting at least mid‑single‑digit growth in fiscal 2027 with emerging biotech the key swing factor. Bio-Techne, J2 Global And InMode Break Out Of Bases, Near Buy Points Bio-Techne (NASDAQ:TECH) reported fiscal third-quarter 2026 results marked by uneven end-market conditions, with strong demand from large pharmaceutical customers and stabilizing U.S. academic trends offset by continued weakness in emerging biotech spending. President and CEO Kim Kelderman said the company “continued to execute with discipline in a dynamic and uneven end market environment,” as the quarter included a 2% organic revenue decline, which management attributed in part to customer and order-timing factors. Total revenue was $311.4 million, down 2% on both a reported and organic basis, according to CFO Jim Hippel. Adjusted EPS was $0.53, down $0.03 from the prior year, while GAAP EPS was $0.32, up from $0.14. Hippel said foreign exchange provided a 2% tailwind to revenue, while the prior divestiture of Exosome Diagnostics created a 2% headwind. → Berkshire Hathaway’s Record Cash Hoard: Why and What's Next? Management again highlighted that timing related to “two of our largest cell therapy customers who received FDA Fast Track designation,” along with the shift of a large OEM commercial supply order into the prior quarter, pressured the quarter by about 400 basis points in total. Kelderman said ex...